Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Recruiting · NCT07252050 · Registry updated 2026-06-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Recruiting | Phase 1 / Phase 2 | 2026-06-04 | NCT07252050 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arkansas Children's Hospital Research Institute | 37 |
| Children's Healthcare of Atlanta | 24 |
| Emory University | 393 |
| Incyte Corporation | 153 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Healthcare of Atlanta | Atlanta | United States | 38 |
| Children's Hospital of Colorado | Aurora | United States | 28 |
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| Manning Family Children's | New Orleans | United States | 1 |